BioAtla Inc (NAS:BCAB)

Q1 2025 Bioatla Inc Earnings Call Transcript

May 6, 2025 / 08:30 PM GMT

Release Date Price: $23.77 (-8.19%)

Transcript 10-Q8-K

Key Points

Positve

BioAtla Inc (BCAB) reported progress in their phase one dose escalation study, with multiple patients achieving tumor reduction and tolerating the therapy over many months without progression.
The company observed exceptional overall survival rates in their cab-axel ADC program, with a two-year landmark survival of 59% in MKRAS non-small cell lung cancer patients.
BioAtla Inc (BCAB) reported a 100% disease control rate in treatment-refractory HPV positive head and neck cancer patients, with a 45% overall response rate.
The company is actively engaged in discussions for potential partnerships to maximize the value of their phase 2 clinical programs.
BioAtla Inc (BCAB) has managed to reduce their R&D expenses significantly, which is expected to provide sufficient runway to fund operations and achieve key clinical readouts in the first half of 2026.

Negative

The company reported a net loss of $15.3 million for the quarter ended March 31, 2025.
Cash and cash equivalents decreased to $32.4 million as of March 31, 2025, from $49 million as of December 31, 2024.
BioAtla Inc (BCAB) had to implement a workforce reduction, which incurred additional charges.
The company has not yet reached the maximally tolerated dose in their phase one study, indicating ongoing uncertainty in dose optimization.
There is a reliance on potential new partnerships to extend their cash runway and support future operations.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

BCAB.OQ - Bioatla Inc
Q1 2025 Bioatla Inc Earnings Call
May 06, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day everyone and welcome to today's Bio Atla 1st quarter 2025 earnings call. At this time, all participants are in a listen-only mode. Later you will have the opportunity to ask questions during the question and answer session.

I will be standing by should you need any assistance. It is now my pleasure to turn the conference over to Bruce Mackle with Lifeci Advisors. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator, and good afternoon, everyone. With me today on the phone from BioAla are Doctor Jay Short, Chairman, CEO and co-founder, and Richard

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.